Launching a new therapy has never been more consequential, or more difficult. Launch windows are shrinking, resources are tighter, government pricing actions are reshaping access strategy, and AI is changing how launch teams are built and how they work. In this environment, what separates a best practice launch organization from the rest? Blue Matter’s Best Practice Launch Organization Study set out to answer that question through in-depth interviews with senior launch leaders at 10 established and emerging biopharma companies.
This white paper presents the five key success factors for pharmaceutical and biotech launch excellence: a team aligned around a clear launch vision, insights that drive action, customer focus, a right-sized launch organization, and agile ways of working. It shares how participating companies rated themselves on each factor, revealing that no organization has yet reached best practice and that the widest gap lies in launch vision and cross-functional alignment. The paper also examines how strengths and gaps differ between emerging and established organizations, and offers practical recommendations for each success factor along with three overarching strategic actions.
